Dr James Eshelby
James is Head of European R&D Business Development at Pfizer, has been leading scientific and business teams at Pfizer for 16 years and is now based at Pfizer's Neusentis research unit in Cambridge UK. James has been in charge of BD teams providing support to Drug Delivery, Pharm Sci Development, Clinical Research, Pain and Regenerative Medicine departments. James is currently Senior Director and Head of Pfizer's European R&D Business Development team that has a successful record in evaluating, negotiating and managing Licensing and Collaboration deals. James has led business development activities on several major and varied alliances with Biotechs, SMEs, Universities, Pharma and public bodies, on behalf of research divisions across Pfizer.
James had previously worked for Zeneca Agrochemicals for eight years. James has a PhD in Chemistry which he gained during his time at Zeneca and is an inventor on nine patents, has several publications to his name and is a frequent speaker at conferences.
Dr Luis Castro
Dr Luis Castro was born and educated in Spain, gaining his BSc and PhD in Organic Chemistry from the University of Santiago de Compostela. Luis started his career in the Pharmaceutical industry at MSD’s Neuroscience Research Centre (Terlings Park, UK) becoming Scientific Site Head in 2005. Following the closure of the Terlings Park laboratories in 2006, he moved to GSK’s Neurology & GI Centre of Excellence for Drug Discovery (N&GI CEDD) as VP Chemistry & DMPK, being responsible for the UK group as well as setting up a Discovery team in Biopolis, Singapore. In 2008 following a rationalisation at GSK Luis took a fresh challenge at Eisai, driving the expansion of its Drug Discovery unit (Biochemistry/Pharmacology, DMPK & MedChem) at the newly created European Knowledge Centre, Hatfield, UK.
Luis joined UCB in 2012 as VP Global Chemistry and over the past 23 years of his Pharmaceutical Industry career, Luis has been associated with approximately 40 development compounds, a number of which are being actively pursued in the clinic or reached the market (e.g. Maxalt). Luis is highly motivated and passionate for chemistry and science in general and in their application to the discovery of innovative medicines.
Dr J. Mark Treherne (Chairman)
Mark has been actively involved in the biopharmaceutical industry for 25 years and was a co-founder and Chief Executive of Cambridge Drug Discovery Limited (CDD), leading the acquisition of CDD for Â£28 million by AIM-listed BioFocus plc, where he then became a Commercial Director of BioFocus, driving significant growth of its profitable services business. Since leaving his full-time position at BioFocus plc in February 2002 to remain on the Board as a non-executive director, Mark has now served on the Boards of over 10 private and public biopharmaceutical companies. In addition to Cyclofluidic, he is currently on the Boards of NeuroDiscovery Limited, Domain Pharmaceuticals SA, Population Genetics Technologies Limited, Senexis Limited and Xention Limited. Dr Treherne has now helped raise more than Â£90 million for various biopharmaceutical businesses over the last 10 years. Dr Treherne was also formerly Chairman of ERBI Limited, which is a not-for-profit organisation that represents the biotechnology companies based around Cambridge in the East of England. Dr Treherne initially trained as a neuroscientist and electrophysiologist at Cambridge University and previously led the Neurodegeneration research group at Pfizer's research facility at Sandwich, UK, until 1997.
UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing approximately 9 000 people in over 40 countries, UCB generated revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext Brussels (symbol: UCB). UCB NewMedicines is UCB's discovery research through to clinical proof of concept organization established to secure the future pipeline of UCB. With strong technology platforms underpinning new products, UCB NewMedicines has an increased emphasis on external research and collaboration to sustain pipeline innovation. UCB NewMedicines was established in 2008 to focus on building the high-value and innovative early pipeline to kick-off the breakthrough phase of UCB's roadmap.
Pfizer - Pfizer Inc: Working together for a healthier world™
Founded in 1849, Pfizer is the world's largest research-based pharmaceutical company taking new approaches to better health. We discover, develop, manufacture and deliver quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals. We also partner with healthcare providers, governments and local communities around the world to expand access to our medicines and to provide better quality health care and health system support. At Pfizer, more than 80,000 colleagues in more than 90 countries work every day to help people stay happier and healthier longer and to reduce the human and economic burden of disease worldwide.